谢小明

中山大学“百人计划”引进人才，教授，博士研究生导师、华南肿瘤学国家重点实验室研究员，肿瘤生物技术研究室主任，《癌症》编辑部责任编委。美国M. D. Anderson癌症中心访问教授。2008年7月回国，与杨名添教授一起建立肿瘤防治中心乳腺科。2009年9月建立华南肿瘤学国家重点实验室肿瘤生物技术研究室，2009年与法国让佩林癌症中心建立中法癌症遗传学联合实验室。

医疗专长：

从事肿瘤和乳腺癌医疗、教学和科研工作二十多年，在乳腺疾病的诊断和治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出。

个人简介:

在中南大学湘雅医学院于1986年获医学学士学位，1994年获博士学位。1995-1997年在西班牙做博士后，1997-1999年在美国佛罗里达大学做博士后，1999-2003年在美国贝勒医学院任副研究员。2003-2008年在美国德州大学M. D. Anderson癌症中心任研究员，曾任分子和细胞肿瘤系转化研究课题组负责人。长期致力于癌症的基因调控，活体成像转基因动物模型和癌症的靶向基因治疗等方面研究，发展了多套新颖的对乳腺癌、胰腺癌、前列腺癌、卵巢癌、肝癌等多种癌症的靶向治疗策略和临床前期产品，与中国、美国、英国、日本、韩国及台湾地区的多家研究机构开展了广泛的交流和合作。

现已在发表论著共发表论著40余篇，在国外发表论著19篇(包括Cancer Cell， Nature Cell Biology，Caner Research，Oncogene, Human Gene Therapy， Mol Cancer Therapeutics, Cancer Gene Therapy， Molecular Endocrinology， Digestive Diseases and Science等)。其中以第一作者发表论文总影响因子52.8分， 1篇大于20(Cancer Cell，2007)，以第一作者 和共同作者发表论文总影响因子累计超过135.2，他引共682余次，其中第一作者论文单篇他引最高60余次，共同作者单篇他引最高69余次;已获得中国美国发明专利3项;研制临床前期产品3项，其中1项已经FDA批准，获许进入一期临床验证。其中纳米颗粒介导的VISA系统靶向治疗胰腺癌的主要研究成果，发表在2007年7月份的Cancer Cell(IF值24.9)上。美国在 Science News 上评论：“这种治疗癌症的方法是独一无二的，对癌症既有非常强的疗效又非常特异”。美国ABC电视台认为“这是癌症治疗的一个重大突破”。在论文发表后短期内，来自美国<<世界日报>>，以及中 国、英 国、俄 国、德 国、法国、西班牙、葡萄牙、意大利、荷兰、希腊、阿拉伯、韩国、日本等世界各地的多家科学杂志和新闻媒体对该成就也纷纷进行了200多次报道和高度的评价。先后承担美国NIH、NCI重大课题5多项，中山大学II类引进人才基金, 广东省自然基金等。

发明专利：

1. CANCER SPECIFIC PROMOTERS (Including breast cancer and ovarian cancer). USPT Patent. 癌症靶向基因治疗乳腺癌和卵巢癌. 美国专利申请: 119430572 (11.2007) (AO-UTSC:995US)。

2. CANCER SPECIFIC PROMOTERS (Including breast cancer, pancreatic cancer, prostate cancer). USPT Patent. 癌症靶向基因治疗乳腺癌, 胰腺癌和卵巢癌. 美国专利: 20050260643。

3. One type of the innovative syringe. China Patent.中国专利: ZL 93233668.X。

临床试验：

2003-Present 乳腺癌临床试验

1. E1A gene therapy for breast cancer; E1A 基因治疗乳腺癌

2. BikDD gene therapy for breast cancer. BikDD基因治疗乳腺癌 (prepared, under process of FDA)

3. E10A (Adenovirus expressing human endostatin) for recurrent breast cancer therapy (approved by SFDA)..

2005-present 胰腺癌临床试验

1. BikDD gene therapy for pancreatic cancer. BikDD基因治疗胰腺癌 (prepared, under process of FDA)

2005-present 卵巢癌临床试

1. E1A gene therapy and SAHA for ovarian cancer. E1A 基因治疗和SAHA治疗卵巢癌

2. BikDD gene therapy for ovarian cancer. BikDD基因治疗卵巢癌 (prepared, under process of FDA)

新闻与报道：

纳米颗粒介导的VISA系统靶向治疗胰腺癌的主要研究成果，已发表2007年7月份的Cancer Cell (IF:24.962)上。

1. 美国约翰霍普金斯大学医学院的胰腺癌专家Scott E. Ken教授，在 Science News 上评论：“这种治胰腺

癌的方法是独一无二的，对胰腺癌既有非常强的疗效又非常特异”。

2. 美国ABC电视台认为“是胰腺癌治疗的一个重大突破”。

3. 来自美国、中国、俄 国、德 国、法国、西班牙、葡萄牙、意大利、荷兰、希腊、阿拉伯、韩国

本等世界各的科学杂志和新闻媒体对该成就纷纷进行了200多次报道，并给予了高度的价。

部分获奖：

1. AstraZeneca Award ($50,000). USA. 2005. 美国.

2. First prize, the 10th Annual Oncology Research Seminar. USA. 2001. 美国.

3. Travel Grant, the 6th Conference on retroviruses and Opportunistic Infections, USA. 1999. 美国.

4. The best oral presentation award. Terapia genica del hepatocarcinoma mediate la transferencia del gen la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain. 1998. 西班牙.

5. Dr. Sir Q.W. Lee fellowship. USA. 1997. 美国.

6. Dr. Li Zhengbie’s Fellowship. China. 1994. 长沙.

7. Challenge Cup of China’s invention. China.1993. 挑战杯奖,上海.

8. <<湘楚青年科技名人录>> (1993年).

9. <<当代发明家成果辞典>> (1994年).

10. <<当代科学家与发明家大词典>> (1994年).

11. <<国际名人词典>> (第23版). 英国国际人物中心转记编辑出版，1994年. <> (Twenty-third Edition).

1. Xie, X., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 24.962).

2. Xie X, J.L Hsu1, M-G Choi1,9, W Xia1, H Yamaguchi, C-T Chen, ZLu2, N T. Ueno, JK. Wolf4, RC. Bast, Jr. and M-Ch Hung. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Therapeutics. 2009; 8(8):2375-82.( IF: 5.13).

3. Xie, X, Z Luo, KM Slawin, and DM Spencer. The EZC-Prostate Model: Non-invasive prostate imaging in living mice. Mol Endocrinol 2004;18(3):722-732. (IF: 4.97).

4. Xie X, X Zhou, Y Liu, K Slawin, and D Spencer. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795-804. (IF: 7.7).

5. Xie X, X Zhou, Y Liu, CYF Young, DJ Tindall, K Slawin, and D Spencer. Robust prostate-specific expression for targeted gene therapy based on human kallikrein 2 (hK2) promoter. Human Gene Therapy 2001;12(5): 549-61. (IF 4.5).

6. Xie X, CE Forsmark, and JY Lau. Effect of bile and pancreatic juice on adenovirus-mediated gene delivery: Implications on the feasibility of gene delivery through ERCP. Digestive Diseases and Sciences 2000; 45(2):230-36. (IF: 1.5).

7. Yang, J-Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J-Y., Lai, C-C., Chang, C-J., Huang, W-C., Huang, H., Kuo, H-P., Lee, D-F., Li, L-Y., Lien H-C., Cheng, X, Chang, K-J., Hsiao, C-D., Tsai, F-J., Tsai, C-H., Sahin, AA., Hortobagyi, GN., Yu, D., Muller, WJ., Mills, GB., and Hung, M-C. Erk promotes tumorigenesis by inhibiting Foxo3a via MDM2-mediated degradation. Nature Cell Biology, 2008; (Feb); 1-11. (IF: 18.5).

8. Seethammagari, M. R., Xie, X., Greenberg, N. M., and Spencer, D. M. (2006). EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 2006;66, 6199-6209. (IF: 7.7).

9. Ding, Q., He, X., Xia, W., Hsu, J-M., Chen, C-T., Li, L-Y., Lee, D-F., Yang, J-Y., Xie, X., Liu, J-C., and Hung, M-C. Mcl-1 inversely correlates with GSK-3β activity and associates with poor prognosis in human breast cancer. Cancer Research, 2007;67(10):4564-71. (IF: 7.7).

10. Ou-Yang, F., Lan, K. L., Chen, C. T., Liu, J. C., Weng, C. L., Chou, C. K., Xie, X., Hung, J. Y., Wei, Y., Hortobagyi, G. N. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006; 66, 378-384. (IF: 7.7).

11. Day, C. P., Rau, K. M., Qiu, L., Liu, C. W., Kuo, H. P., Xie, X., Lopez-Berestein, G., Hortobagyi, G. N., and Hung, M. C.. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 2006;13, 706-719. (IF: 4.2).

12. Sher YP, T-F Tzeng, S-F Kan, J Hsu, X Xie, Z Han, W-C Lin, L-Y Li, and M-C Hung. Cancer Targeted Gene Therapy of BikDD Inhibits Orthotopic Lung Cancer Growth and Improves Long-Term Survival. Oncogene. 2009.( IF: 6. 2).

13. Lau J Y-N, X Xie, MMC Lai, and PC Wu. Apoptosis and viral hepatitis. Seminar in Liver Disease 1998; 18(2):169-176.

14. Lasarte JJ, FJ Corrales, N Casares, A Lopez-Diaz de Cerio, C Qian, X Xie, F Borras-Cuesta, and J Prieto. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministrered antigen: the role of nitric oxide. J Immunology, 1999; 162:5270-5277.

15. Mazzolini G, C Qian, X Xie, Y Sun, JJ Lasarte M, Drozdzik, J Prieto. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Therapy, 1999; 6(6): 514-22.

16. M Drozdzik, C Qian, X Xie, JJ Lasarte, J Prieto. Gene therapy of hepatoma model by combination of adenovirus expressing the HSV thymidine kinase and interleukin-12. J Hepatology. 2000; 32(2): 379-86.

17. Mazzolini G, C Qian, I Narvaiza, M Barajas, F Borras-Cuesta X Xie, M Duarte, I Melero and J Prieto. Adenoviral gene transfer of Interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effect level. Human Gene Therapy 2000; 11:113-25.

18. Zhao T, XM Rao, X Xie, L Li, T Thompson, KM McMasters, and HS Zhou. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003;63(12):3073-8.

19. Tuttle, D. L, CR Coberley, X Xie, ZC Kou, JW Sleasman, and MM Goodenow. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. AIDS Res Hum Retroviruses, 2004. 20(3): 305-13.

部分国际会议(* 为第一作者或通信作者文摘)：

*1. The 8th International Conference on Viral Hepatitis. Xie X, X Su, et al. A comparative study of on the relationship of HBV, HCV and HDV with hepatocellular carcinoma. Beijing, China. 1993北京

*2. The annual meeting of the Association for the Study of Liver Diseases. Xie, et al. In vivo gene transfer to hepatocullular carcinoma in experimental animal models by adenoviral vector. London, 1996. 伦敦

*3. The 2rd annual meeting of the Europe Society of Gene Therapy. X Xie, M Idoato and J Prieto. In vivo gene transfer to hepatocullular carcinoma by adenoviral vector. London, 1998. 西班牙

*4. The 48th annual meeting of the American Association for the Study of Liver Diseases. Xie X, CE Forsmark and JYN Lau. Feasibility of adenoviral-mediated gene delivery through EGFP: the effect of bile and pancreatic juice. Chicago, USA, 1997. 芝加哥

*5. The 6th Conference on retroviruses and Opportunistic Infections. Xie X, D Turtle, J.W. Sleasman and M.M. Goodenow . CD4 T lymphocytes that coexpress CD45RO and CD45RA are the primary target cells for infection by HIV-1. Chicago, USA, 1999. 芝加哥

*6. The 3rd annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Robust prostate cell-specific expression based on human kallikrein 2(hK2) has been developed for targeted gene therapy. Denver, USA, 2000. 丹佛

*7. The 4th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Seattle, USA, 2001. 西雅图

*8. The 5th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel gene therapy for prostate cancer: in vivo-targeted expression of the E.Coli purine nucleoside phsophorylase gene by adenoviral delivery. Boston, USA, 2002. 波士顿

*9. The 6th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel prostate model. Washington DC, USA, 2003. 华盛顿

*10. The 8th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted prostate cancer gene therapy (oral presentation). St. Louis, USA, 2005圣路易斯

*11. The 10th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models (oral presentation). Seattle, USA, 2007. 西雅图

*12. IMPcCT (Innovative Minds in Prostate Cancer Today), Department of Defense. Xie X, et al. Targeted expression of BikDD cures AIPC and ADPC in noninvasive imaging models. Atlanta, USA, 2007.

13. The 5th Chinese Conference on Cancer and International Gene Therapy. Shijianzhuan, Hebei,China, 2008.

*14. The 15th World Congress on Breast Diseases and 3rd Shanghai Breast Cancer Symposium. Shanghai, China, Oct. 2008. 上海

15. The San Antonio Breast Cancer Symposium at An Antonio, USA. Dec 10-15. 2008. 圣奥东尼奥

*16. The 5th Conference on Cancer Translational Research. Xie et al. “VISA” nanopaticles to breast cancer. Feb. 19-21. 2009. Macau.

17. The St Gallen Oncology Conference in Switzerland. March 11-15, 2009. 瑞士

18. The 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, USA. May 28-June 3. 2009. 奥尔兰多

*19. the 14th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA” nanopaticles targeting to breast cancer. Nov. 11-14. Hong Kong. 香港

*20. The San Antonio Breast Cancer Symposium at An Antonio. Xiaoming Xie, et al. “VISA” nanopaticles to breast cancer. USA. Dec 9-14. 2009. 圣奥东尼奥

1.中华医学会学会会员 (1990年)。

2.美国科学促进会(AAAS)(1998年)。

3.美国基因治疗协会(ASGT)会员 (1999年)。

4.美国 Sigma Xi 科学研究会会员(2000年)。

5.美国癌症研究协会会员(AACR)，(2004年)。

6.美国临床癌症研究协会(ASCO)(2008年)

华南肿瘤学国家重点实验室研究员，肿瘤生物技术研究室主任，《癌症》编辑部责任编委。美国M. D. Anderson癌症中心访问教授

在乳腺疾病的诊断和治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出

1. Co-Investigator, E1A Gene Therapy in Breast Cancer, RO1 CA058880, National Cancer Institute, NIH $261,000 ADC, 08/01/1997-01/31/2005.

2. Co-Investigator, “Targeting Breast Cancer-Specific Gene Therapy’ in NIH SPORE grant in Breast Cancer (5P50CA116199-03), 2005-2010.

3. Co-Investigator, “Development of Novel Gene Therapy for Pancreatic Cancer” in NIH SPORE grant in Pancreatic Cancer (P20 CA101936), P20 CA101936-01, NCI,NIH. $225,000 (ADC). 07/01/2003-06/30/2008.

4. Co-Investigator. “Development of E1A Gene Therapy in Ovarian Cancer” in NIH SPORE grant in Ovarian Cancer (5P50CA083639-08), 2005-2010.

5. Co-PI. Ideal Development Award ($560,000), DOD (Department of Defense).USA. 2007.

6. Co-Investigator, Topfer Funds.2005-2010.

7. Co-Investigator, M. D. Anderson Cancer Center Support Grant CA16672, 2005.

8. Co-Investigator, NIH Grant R01-CA87569, Baylor College of Medicine, 2001-2006.

9.PI. 中山大学“985” 计划(2008089);800,000 RMB, 2008-2010

10. PI. 广东省自然基金 (9151008901000124): 50,000 RMB, 2009-2011.